Myeloma Foundation Draws Attention to Cancers and Ground Zero

Last month, members of the International Myeloma Foundation (IMF) held a congressional briefing to draw attention to the risk of toxin exposure and multiple myeloma.

"The latest update from the World Trade Center health Program reveals more than a doubling of the number of cancer cases since last year at this time," said Brian GM Durie, MD, IMF Chairman and co-founder. "If the numbers continue at this pace, the burden of cancer, including myeloma, will become enormous-- costly in terms of both lives and dollars."

Durie noted that 2,157 first responders on 9/11 have developed cancer, and that multiple myeloma was among the top four cancers reported.

Other physicians gave presentations to Congress but few held the attention of the elected officials quite like Patricia Workman, a volunteer at the World Trade Center site who has since developed myleoma offered her own firsthand account of working conditions at Ground Zero.

"Now that I know all there is to know about what took place at Ground Zero, I would not change one thing that I did," she said in a press release. "I regret that I wasn’t able to do more."

Source: Healio

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap